Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41467-021-22362-2 http://scihub22266oqcxt.onion/10.1038/s41467-021-22362-2 33795671!8016852!33795671     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Commun 2021 ; 12 (1): 2016 Nephropedia Template TP {{tp|p=33795671|t=2021. Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors |pdf=|usr=}}{{33795671}} gab.com Text Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors JO: Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=33795671 #FOAvip We report the identification of three structurally diverse compounds - compound 4, GC376, and MAC-5576 - as inhibitors of the SARS-CoV-2 3CL protease. Structures of each of these compounds in complex with the protease revealed strategies for further development, as well as general principles for designing SARS-CoV-2 3CL protease inhibitors. These compounds may therefore serve as leads for the basis of building effective SARS-CoV-2 3CL protease inhibitors. Twit Text FOAVip Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors ????Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=33795671 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33795671 #FOAvip English Wikipedia <ref>{{Cite pmid|33795671}}</ref> Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors #MMPMID33795671 Iketani S; Forouhar F; Liu H; Hong SJ; Lin FY; Nair MS; Zask A; Huang Y; Xing L; Stockwell BR; Chavez A; Ho DD Nat Commun 2021[Apr]; 12 (1): 2016 PMID33795671show ga We report the identification of three structurally diverse compounds - compound 4, GC376, and MAC-5576 - as inhibitors of the SARS-CoV-2 3CL protease. Structures of each of these compounds in complex with the protease revealed strategies for further development, as well as general principles for designing SARS-CoV-2 3CL protease inhibitors. These compounds may therefore serve as leads for the basis of building effective SARS-CoV-2 3CL protease inhibitors. |*COVID-19 Drug Treatment[MESH] |Coronavirus 3C Proteases/*antagonists & inhibitors[MESH] |Crystallography, X-Ray[MESH] |Drug Evaluation, Preclinical[MESH] |Humans[MESH] |Pyrrolidines/pharmacology[MESH] |SARS-CoV-2/*drug effects[MESH] |Sulfonic Acids[MESH]Lead compounds for the development of SARS-CoV-2 3CL protease inhibito(epmc).pdf DeepDyve Pubget Overpricing